⌘K
Loading ticker…
As of 2026-08-24, Calidi Biotherapeutics, Inc. (CLDI) has a 3-month relative strength percentile of 5 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 24. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 11.6%, relative volume 0.19×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CLDI is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -30.6% / -85.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CLDI appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $6K notional.
Held by 1 ETFs · $6K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $6K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLDI Jan avg: -31.30% median: -34.07% win: 0% σ: 17.27% n: 3 2023-09-14 → 2026-07-31 | CLDI Feb avg: -10.49% median: -22.09% win: 33% σ: 23.00% n: 3 2023-09-14 → 2026-07-31 | CLDI Mar avg: -36.98% median: -35.62% win: 0% σ: 32.32% n: 3 2023-09-14 → 2026-07-31 | CLDI Apr avg: -27.01% median: -14.78% win: 0% σ: 34.05% n: 3 2023-09-14 → 2026-07-31 | CLDI May avg: -17.30% median: -21.94% win: 0% σ: 13.05% n: 3 2023-09-14 → 2026-07-31 | CLDI Jun avg: -12.40% median: -8.11% win: 33% σ: 20.15% n: 3 2023-09-14 → 2026-07-31 | CLDI Jul avg: 32.61% median: -21.50% win: 33% σ: 109.87% n: 3 2023-09-14 → 2026-07-31 | CLDI Aug avg: -52.15% median: -52.15% win: 0% σ: 35.02% n: 2 2023-09-14 → 2026-07-31 (current) | CLDI Sep avg: -13.34% median: -7.88% win: 33% σ: 16.75% n: 3 2023-09-14 → 2026-07-31 | CLDI Oct avg: -9.87% median: 1.32% win: 67% σ: 21.30% n: 3 2023-09-14 → 2026-07-31 | CLDI Nov avg: 24.69% median: -1.95% win: 33% σ: 47.63% n: 3 2023-09-14 → 2026-07-31 | CLDI Dec avg: -32.12% median: -28.09% win: 0% σ: 12.13% n: 3 2023-09-14 → 2026-07-31 |